ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Recurrence
Cognitive Dysfunction

Multiple Sclerosis (MS) trials near Barcelona, CT, ESP:

Locations recently updated

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (Mintaka)

The main purpose of this study is to assess the efficacy of RO7268489 in adults with progressive multiple sclerosis (PMS) receiving...

Enrolling
Progressive Multiple Sclerosis
Drug: RO7268489
Drug: Ocrelizumab

Phase 2

Roche
Roche

Barcelona, Spain and 15 other locations

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO)

SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sc...

Enrolling
Multiple Sclerosis
Drug: Ocrelizumab Reference Formulation
Drug: Ocrelizumab Test Formulation

Phase 2

Roche
Roche

Barcelona, Spain and 40 other locations

Virtual Reality - Gamma Sensory Stimulation for Improving Fatigue in People With Multiple Sclerosis (VR-GSS)

delivered via a Virtual Reality (VR) headset in individuals with Multiple Sclerosis (MS) who experience moderate to severe...

Not yet enrolling
Multiple Sclerosis
Device: Virtual Reality Sham Sensory Stimulation
Device: Virtual Reality Gamma Sensory Stimulation
Clarity Health Technologies

Barcelona, Barcelona, Spain

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (MAXIMS)

the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...

Active, not recruiting
Progressive Multiple Sclerosis
Drug: Placebo
Drug: Masitinib (4.5)

Phase 3

AB Science
AB Science

Barcelona, Spain and 36 other locations

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

(Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple...

Enrolling
Multiple Sclerosis
Drug: RO7121932 IV
Drug: RO7121932 SC

Phase 1

Roche
Roche

Barcelona, Spain and 31 other locations

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...

Active, not recruiting
Multiple Sclerosis, Relapsing-Remitting
Drug: Interferon beta type 1a
Drug: BIIB017 (peginterferon beta-1a)

Phase 3

Biogen
Biogen

Esplugues de Llobregat, Barcelona, Spain and 65 other locations

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS) (Operetta 2)

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: Ocrelizumab
Drug: Fingolimod

Phase 3

Roche
Roche

Barcelona, Spain and 102 other locations

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascendi...

Enrolling
Progressive Multiple Sclerosis
Biological: rapcabtagene autoleucel (YTB323)

Phase 1, Phase 2

Novartis
Novartis

Barcelona, Catalonia, Spain and 16 other locations

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

kinetics of YTB323 in approximately 28 participants with Relapsing Multiple Sclerosis (RMS) with breakthrough disease activity duri...

Enrolling
Relapsing Multiple Sclerosis
Biological: rapcabtagene autoleucel (YTB323)

Phase 1, Phase 2

Novartis
Novartis

Barcelona, Spain and 16 other locations

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Barcelona, Spain and 209 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems